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Abstract 
Background: Adherence issues in polycystic ovary syndrome (PCOS) patients have 
not been examined thoroughly. Patients report prolonged periods of treatment and 
side effects of the drug as the most common reason for withdrawal from treatment. 
To improve the effective management of PCOS patients, it is fundamental to 
understand facilitating and inhibiting factors to treatment adherence. 
Objective: To explore facilitating/inhibiting factors related to treatment adherence 
among PCOS patients.  
Materials and Methods: This was a qualitative study with a purposive sample of 
women with confirmed diagnosis of PCOS. The data were collected via 20 in-depth 
semi-structured interviews with women aged between 21-34 yr. A qualitative 
content analysis was used to analyze the data. 
Results: Five themes were identified which described different types of facilitating/ 
inhibiting factors to treatment adherence. Inhibiting factors included financial issues, 
patient-related, disease-related, and health care provider-related factors; while social 
factors were found to be both facilitating and inhibiting.  
Conclusion: The findings suggest that successful adherence to PCOS treatment is 
highly dependent on patients recognizing and adapting to financial, social, and 
health care related inhibiting factors. It is also crucial for clinicians and policy 
makers to recognize these key inhibiting factors in order to improve treatment 
outcomes. 
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Introduction 
 
olycystic ovary syndrome (PCOS) is 
the most common endocrine 
disorder in women of childbearing 
age. It is estimated that 16.5% of women 
suffer from the disease (1). The symptoms 
typically associated with PCOS include 
amenorrhea, oligomenorrhea, hirsutism, 
obesity, infertility, anovulation, and acne. 
These symptoms can lead to depression, 
marital and social maladjustment and 
impaired sexual functioning (2). 
Effective treatment for PCOS may include 
oral contraceptives, progesterone, metformin, 
anti-androgens as well as lifestyle modification 
and/or weight loss (3). Therefore, achieving 
effective management of PCOS and reduction 
of clinical complications requires a prolonged 
compliance with multiple prescribed drugs and 
changes in lifestyle. The term compliance has 
mostly been superseded by the term 
adherence, a similar concept but one that has 
more positive implications for the 
physician/patient relationship. Using 
compliance was heavily criticized, as it 
conveyed a negative image of the relationship 
between patient and prescriber, where the 
role of the prescriber seemed to be to issue 
instructions to the patient who had to follow 
the prescriber‟s orders. Noncompliance, then, 
was interpreted as patient incompetence – not 
being able to follow instructions, or deliberate, 
self-sabotaging behavior. The term adherence 
recognizes a patient‟s right to choose to follow 
a doctor‟s suggested treatment plan. 
A World Health Organization report 
suggests that 50% of patients from developed 
countries with chronic disease do not use their 
medications as recommended (1). In 
developing countries, in addition to poor 
P 
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access to health care, lack of appropriate 
diagnosis and limited access to medicines, 
poor adherence seriously threatens any effort 
to tackle chronic illness. As an example In the 
United States for example, non-adherence to 
medical regimens has been estimated to cost 
the US health-care system $100 billion per yr 
(2-4). Therefore, the outcome of non-
adherence is loss: loss of opportunities for 
patients to improve their health, and loss of 
medication efficacy by health-care systems, 
with the subsequent effect of increased 
morbidity. However, adherence issues in 
PCOS patients have not been examined 
thoroughly. Patients report prolonged periods 
of treatment and side effects of the drug as 
the most common reason for withdrawal from 
treatment. To improve the effective 
management of PCOS patients, it is 
fundamental to understand facilitating and 
inhibiting factors to treatment adherence.  
Therefore, the aim of this study was to 
explore PCOS patients‟ views about 
facilitating and inhibiting factors to adherence. 
 
Materials and methods 
 
Study design 
This was a qualitative study using the 
content analysis method. In the conventional 
content analysis, coding categories are 
derived directly from the text data (4). 
Therefore, we used a similar approach as 
recommended. 
 
Participants 
Participants with a confirmed diagnosis of 
PCOS according to Rotterdam criteria 
attending the outpatient Gynecology Clinics in 
Yasuj and Kashan, Iran, were invited to 
participate in the study. Before their clinic 
appointment, women participated in a semi-
structured interview administered by a trained 
research assistant in a private setting. 
Participants were eligible if they met each of 
the criteria presented in table I. Ten women 
refused to participate; no attempt was made to 
determine why those women did not contact 
the researcher. 
Data collection 
Interviews were arranged to suit 
participants. Researchers facilitated a calm 
and familiar place to interview patients. A 
trained qualitative researcher conducted the 
interviews. The lead author of the study 
supervised all data collection to ensure quality 
control. Participants were encouraged to 
openly discuss their opinions. No personal 
information including names or other 
identifying data was obtained and participants 
were able to leave the study at any time.  
At the start of each interview, the 
interviewer introduced herself briefly to talk 
about the purpose of the study and obtain 
consent to record the interview. In-depth, 
semi-structured face-to-face interviews were 
undertakenexplore the ideas, opinions, and 
perceptions about facilitating /inhibiting factors 
of adherence to treatment among Iranian 
patients with PCOS. 
Interviews started with general questions 
(Tell me about your experiences and 
perceptions about PCOS, What facilitating or 
inhibiting factors exist in PCOS care?, what is 
your opinion about making regular scheduled 
PCOS care visits when not having health or 
medication problems) with follow-up questions 
to explore their answers. To avoid participants 
feeling that there was right or wrong answers, 
the emphasis was placed on questions 
starting with “How” and “What” as well as 
explorative questions.  
Data were collected until saturation of the 
data was reached; this occurred when no 
codes were apparent in the data. Saturation 
point was reached after analysis with 
participant 18. The duration of each interview 
depended on the tolerance and interest of the 
participant and varied from 20 to 89 min 
(mean 42 min). 
 
Ethical considerations 
The Ethics Committee of the Yasuj Medical 
University approved the study (23/2/893). All 
participants gave informed consent to publish 
the details of their interviews. Pseudonyms 
have been used to protect the women‟s 
anonymity. 
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Statistical analysis 
Tapes were transcribed verbatim and 
reviewed repeatedly to extract key sentences 
and words of the texts; codes was given to 
each key word or sentence. Then similar 
codes were grouped to create categories and 
compacted to form themes. Data entry into 
MAXQDA and analysis were undertaken. 
To enhance rigour and reliability of the data 
analysis, other researchers in addition to the 
primary researcher were involved in peer 
checking. The main investigator read the 
transcripts to confirm the coding and 
categories and then checked the primary 
researcher‟s interpretations. Credibility was 
enhanced by member checkingby a few 
participants contacted after the analysis. The 
overall level of agreement about peer 
checking and member checking was above 
95%. The maximum variation of sampling and 
prolonged engagement increased the 
credibility of data. 
 
Results 
 
This study comprised of semi-structured 
interviews with 20 patients with PCOS. The 
characteristics of participants showed 
maximum variation within the sample. Patients 
were aged between 21-34 yr; having primary 
to higher educational level; and had 
experienced PCOS from 1-10 yr. Five main 
themes emerged from the analysis: inhibiting 
factors to treatment adherence which included 
financial issues, factors related to patients 
themselves, to the disease, and to the 
healthcare provider system. Social factors 
included both facilitating and inhibiting factors 
(Table II).  
 
Financial issues as inhibiting factor to 
treatment adherence 
In this study, the participants reported the 
money as an inhibiting factor to adherence. 
For example: “My main problem is that I can‟t 
visit a good gynecologist for its cost. It is a big 
burden for me.” participant [P aged 22]. 
Another patient stated: “I went to 
gynecologist twice and never followed it up 
because of financial problems. The drug was 
very expensive. Now, I got loan to continue 
the treatment.” [P aged 25]. 
 
Patients themselves as inhibiting factor to 
treatment adherence 
In-depth interviews with all participants 
recognized the following patient-related 
inhibiting factors to adherence with the 
treatment:  
a) Perception about PCOS 
A 27-year-old participant told us about the 
wrong perception she held about PCOS: 
“Because I heard that PCOS is something 
usual in women on television, it was also 
usual for me. In other word, I thought that I 
wasn‟t alone; there were many people like me. 
Therefore, I quitted the treatment.” [P aged 
27]. 
b) Knowledge about PCOS  
Some of the participants pointed out that 
they did not have any information about 
PCOS which considered as inhibiting factor in 
following up of the treatment: “I didn't know 
what PCOS was; I thought that it was a 
disease that would be resolved after six 
months. I didn‟t think that this disease was 
ongoing” [P aged 24]. A 25 year old 
participant told us about wrong knowledge 
about PCOS: “I initially had menstrual 
irregularities problem, but since this is usual in 
my family and all have this problem, I never 
followed up.” [P aged 25]. 
 
Social factors included both facilitating 
and inhibiting factors  
a) Family support 
Better understanding among family 
members was something that improved 
adherence. Some interviewees recalled how 
their families helped them: “My family always 
gives me comfort that it‟s not a big deal. Even, 
they come to clinic with me. They always say 
that it‟s nothing, you will be pregnant, we were 
like you too.” [P aged 22]. 
One interviewee said: “My husband always 
reminds me that I used to take my drugs 
regularly. He kept telling me not to forget my 
pills. He had supported all around my life.” [P 
aged 26]. However, some of the participants 
reported non accompaniment of their 
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husbands as an inhibiting factor of adherence: 
“When the doctor advised me to have 
intercourse with my husband for pregnancy 
every other day, my husband didn‟t accept it. 
He said it was ridiculous. If those plans 
worked, we would have a baby since four 
years ago.” [P aged 27]. 
b) Friends support 
Some interviewees recalled how their 
friends helped them in following up the 
treatment. One interviewee, a 27-year-old 
woman, told us about the positive effects of 
friend support as an inhibiting factor to 
adherence: “One of my friends comes to our 
home every time, she tells us promising and 
hopeful words. My mood improved and I 
followed my treatment.” [P aged 27]. 
c) Peer support 
Some participants pointed out to positive 
and others to negative roles of peers in 
adherence to treatment. For example: “I spoke 
to those people just like me. They told me that 
they spent several million Tomans Iranian 
currencies. It did not work. Do not seek the 
treatment. Therefore, I did not go for the 
treatment.” [P aged 27]. A 24-year-old 
participant talked about peer support as an 
inhibiting factor to adherence: “For the 
diagnosis of PCOS, the doctor advised 
hysterosalpingography. Others told me it was 
very painful. I feared and did not follow it up.” 
[P aged 24]. 
 
Disease as inhibiting factor to treatment 
adherence  
Disease-related issues including side 
effects and prolonged time required for 
treatments are the most discussed themes in 
this study. 
a) Side effects of medication 
Most participants had experienced side 
effects of drugs including pain related 
diagnosis or evaluation of drug consumption, 
lethargy, anorexia, hot flushing, and mastalgia 
which increased non-adherence: “When 
taking these medications, I was always hot 
with hot flashes. I felt too much pain in my 
lower abdomen.” [P aged 27]. One 
interviewee said: “Taking the pills, I was too 
anorexic, I had very hot flash.” [P aged 24]. 
b) Prolong time needed for treatment  
The length of the time taken for the entire 
process was mentioned as an inhibiting factor: 
stay on the waiting list to visit a doctor in 
addition to the subsequent time needed for 
the treatment of PCOS took „too long‟. “To 
visit a gynecologist, I had to sit from morning 
to noon in the waiting room of the clinics. It is 
extremely frustrating so I didn‟t visit the doctor 
for about 2 months.” [P aged 27]. Another one 
stated: “I cannot put up with going to doctor 
repeatedly. For that reason, I discontinued 
following up the treatment.” [P aged 28]. 
 
Healthcare provider system as inhibiting 
factor to treatment adherence 
Participants‟ experience revealed that 
health care providers‟ negligence to recognize 
the patient‟s psychosocial needs for an 
effective adherence especially the below 
issues are considered inhibiting factors to the 
treatment: 
a) Lack of informational support 
Not informing the participants about the 
options of the treatment during the first 
consultation was considered as inhibiting 
factor: “My doctor did not explain about my 
disease at all. She only prescribed my drugs.” 
[P aged 27]. “Whenever I went to the clinic, 
she asked me to get ready for sonography. 
After that, she prescribed drugs and said 
good-bye! This ambiguous situation is too 
excruciating for me.” [P aged 34]. 
b) Absent of holistic care  
Some participants pointed out that they had 
experienced the inattention to the health care 
providers about the whole needs for privacy, 
both emotional and physical, and continued: 
“Every time, 3-4 patients were also inside the 
room with the doctor. When I had a vaginal 
ultrasound, several women were sitting inside 
the room and it was very inconvenient.” [P 
aged 26]. “Every time, some patients were 
inside the room and I was embarrassed that 
someone would hear my words. Several 
times, I decided to tell her about my relation 
with my husband but it‟s impossible in the 
presence of the others.” [P aged 28]. 
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Table I: Inclusion criteria 
Desire to participate in the study 
Being 15-40 ys old 
Married 
Absence of non-classic adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia 
Having two of the following Rotterdam diagnostic criteria: 
1) Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume >10 
ml) 
2) Clinical signs of hyperandrogenism (hirsutism score based on hirsutism score greater than 7 or obvious acne), 
3) Having an interval between menstrual periods >35 days and/or amenorrhea, defined as the absence of vaginal bleeding for at least 6 months (i.e. 
199 days) 
No problems in speaking or listening 
Iranian 
Not taking any prescription medication (except allergy medications and occasional pain medications) for at least three months before entering the 
study 
 
Table II: Main themes  
1) Financial issues as inhibiting factor to treatment adherence  
2) Patients themselves as inhibiting factor to treatment adherence 
2a) Perception about PCOS 
2b) Knowledge about PCOS 
3) Disease as inhibiting factor to treatment adherence  
3a) Side effects of medication 
3b) Prolong time needed for treatment 
4) Healthcare provider system as inhibiting factor to treatment adherence  
4a) lack of informational support 
4b) Absent of holistic care 
5) Social factors included both facilitating and inhibiting factors  
5a) Family support 
5b) Friend support 
5c) Peer support 
PCOS: polycystic ovary syndrome 
 
Discussion 
 
The findings from this qualitative study 
indicated that there were five reasons for 
treatment non-adherence among patients with 
PCOS. In PCOS treatment, when combined 
as the cause of sub-fertility, successful 
outcomes of treatment depend upon patient 
adherence to the prescribed treatment. In our 
study, failure of the healthcare professional to 
provide information and lack of dignified care 
were described as inhibiting factors to 
treatment adherence. No other studies have 
found this to be an influencing factor in 
treatment adherence. Previous studies into 
adherence to medication suggest factors 
related to the number of drugs, dosage, 
treatment period, cost and the time between 
starting to observe clinical effects rather than 
the relationship with healthcare professionals 
(6, 7).  
In addition, most patients in this study 
expressed concerns about dignity, privacy, 
respect, and communication. These are in 
agreement with previous studies where 
women with PCOS felt poor communication 
with health care systems and their emotional 
and psychosocial needs were not met (8-10). 
Lack of information has been shown to be 
associated with the poor health-related quality 
of life in this group (11). Providing information 
improves the quality of life in women with 
PCOS and education about their condition 
improves their understanding of causes and 
treatment choices (12). Women with PCOS 
would like to receive information about their 
conditions from doctors (13). In a study by 
Weiss et al many of PCOS women in regard 
to patient-provider relationship reported 
frustration with delays in diagnosis and 
distress about the limited information they 
received about PCOS, and what they needed 
to truly take control of their health (14). 
Moreover, in another qualitative study, it was 
demonstrated that participants described 
receiving insufficient information from health 
care professionals and negative experiences 
in relation to the diagnosis and management 
of their condition (15).  
However, inattention to the holistic care of 
patients remains a problem for other 
conditions (16). The previous study suggested 
that one reason for non-adherence with health 
care plan is inattention to psychosocial needs 
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of the patients and only focus on the medical 
prescription (17). Health care providers played 
an important role in supporting and 
encouraging the patients to adhere to their 
treatments. Good relations with patients 
improved adherence as it has been found 
before (18). Health care providers who spent 
time explaining issues to the patients 
positively influenced the adherence (19). Care 
providers should promote optimal adherence 
by giving clear instructions, providing 
adequate help to handle possible side effects 
of the treatment in order to get better 
adherence. The previous study reported that 
patient-based care is more required than 
diseasebased approach with attention to all of 
the patients‟ needs including physical, 
psychological, social, mental, and spiritual 
needs. Patient-based care helps the patient to 
improve the effective engagement to manage 
their diseases. According to the results of 
several studies, the interactions between 
physicians and healthcare team cause to 
improve the continuity of patient care and 
disease management (20, 21). Some studies 
suggested that patients‟ education and 
involvement in the treatment practice can 
improve health care team efforts for the 
management of a chronic disease through a 
set of interactions with the patient and family 
members (22). 
Based on the participants‟ views, social 
support was found to be crucial for patients' 
treatment. Better understanding among 
community members was spoken of as 
something that improved adherence. The 
previous study has shown that adherence is 
1.74 times higher in patients from supportive 
families (23). The finding of family support as 
a motivator of PCOS treatment was similar to 
that of other studies that found those with 
family support was more likely to practice 
treatment (24-26). However, in our study 
negative role of peer support was as inhibiting 
factors in adherence with treatment that needs 
more attention in a future study. It is known 
that families can be supportive by 
encouraging patients to engage in physical 
activity (27). Social relationships are an 
important factor in maintaining changes, and 
peer support as a facilitator to behavior 
change is also recognized (28, 29). It seemed 
that support and assistance from a family 
member or friend would foster more positive 
attitudes toward disease. 
Moreover, financial status was mentioned 
as inhibiting factor to the adherence of 
participants. Insurance status may have 
prevented patients from following up the 
treatment. Participants mentioned that they 
often could not afford to visit the health care 
providers to repeat prescription schedule. 
Thus, financial issues emerged as a key 
theme. Participants were worried and reported 
that monthly repeated prescriptions caused 
difficulties in adherence. This is a useful 
finding and it is important that policy makers 
working toward the practice of this disease 
consider subsidy and insurance when 
designing PCOS treatment programs. 
Finally, our findings indicated that patients‟ 
beliefs and knowledge regarding disease 
strongly influenced their adherence. The 
previous study associated with antiviral 
therapy in HIV related treatment has depicted 
that education levels and educational 
programs affect adherence (30). It seemed 
that providing better information about PCOS 
increases the patient maintenance in the 
treatment. Health care providers should offer 
information and consult through cables such 
as TV, newspapers, and media to increase 
attention focus on this disease. 
Although this study was strong in many 
ways, it was not without limitations. Simply 
because this study was intended to be a 
qualitative study, the main limitation was 
related to the sample size and number of 
participants; this, in turn, limits generalization. 
The study was carried out with women who 
had sought care in health clinics and it might 
not be representative of the general 
population of the women. Moreover, the study 
was conducted in limited geographical areas 
and may not reflect the experiences of Iranian 
women. 
 
Conclusion 
 
The findings suggest that successful 
adherence to PCOS treatment is highly 
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dependent on removing a range of different 
inhibiting factors including financial, social, 
and health care related inhibiting factors. 
Indeed it is crucial for clinicians and policy 
makers to recognize these key inhibiting 
factors in order to improve treatment 
outcomes. 
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